OR WAIT null SECS
The companies work to develop and supply advanced cell models that better reflect an in-vivo environment to improve drug discovery accuracy and efficiency.
In a distribution agreement announced on July 19, 2021, Lonza will supply a selection of hepatic cells to be prequalified by CN Bio and used in their PhysioMimix organ-on-a-chip (OOC) range of single- and multi-organ microphysiological systems, which aims to change how human-relevant preclinical data is generated. The companies’ shared goal is to develop and supply advanced cell models that better reflect an in-vivo environment to improve drug discovery accuracy and efficiency. Customers can avoid having to trial numerous cell types with prequalified cells. Having high-quality cells that are known to grow successfully in 3D culture will also help fast-track OOC adoption and customer research.
The use of physiologically relevant in-vitro models drives down attrition rates and boosts the efficiency and success of drug discovery programs. Standard 2D cell culture fails to accurately reflect the complex interactions in the body, and animal models are slow, expensive, and can have different reactions than humans. Models, such as OOC, offer another option in research.
“We’re delighted to be working with Lonza, a world-leading cell supplier, to ensure that the prevalidated cells we supply for use with our PhysioMimix single-and multi-organ MPS are of reliably high quality and are well-suited to culture in 3D,” said Tomasz Kostrzewski, director of biology at CN Bio. “Using prequalified cells will save our customers valuable time and resource, further helping to accelerate their drug development journey.”